Abbott Announces Results of Tender Offer and Consent Solicitation for CFR International SpA 5.125% Senior Notes due 2022

ABBOTT PARK, Ill., Jan. 15, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the results of the tender offer and related consent solicitation commenced by its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), to purchase for cash any and all of the outstanding 5.125% Senior Notes due 2022 (the "Notes") issued by CFR International SpA, a Chilean corporation and subsidiary of ALH. The tender offer and related consent solicitation expired at 12 p.m., New York City time, on Jan. 14, 2015. Abbott has been advised that an aggregate of $294,093,000 principal amount of Notes, representing 98% of the outstanding Notes, was tendered, including the $292,893,000 principal amount of Notes that was previously tendered and purchased. ALH has accepted for payment all Notes that were validly tendered and not subsequently withdrawn or previously purchased. 

About Abbott
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Private Securities Litigation Reform Act of 1995 – A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2013, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abbott-announces-results-of-tender-offer-and-consent-solicitation-for-cfr-international-spa-5125-senior-notes-due-2022-300020845.html

SOURCE Abbott

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.